Education
About Us
Working with TipRanks
Follow Us
Zelira Therapeutics (ZLDAF)
OTHER OTC:ZLDAF
ZLDAF Stock Chart & Stats
$0.21
-$0.03(-7.39%)
At close: 4:00 PM EST
$0.21
-$0.03(-7.39%)
Day’s Range― - ―
52-Week Range$0.20 - $0.48
Previous CloseN/A
Volume342.00
Average Volume (3M)189.00
Market Cap
$4.18M
Enterprise Value$8.08M
Total Cash (Recent Filing)$5.66K
Total Debt (Recent Filing)$2.14M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,897,155
10 Day Avg. Volume15
30 Day Avg. Volume189
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.13
Price to Sales (P/S)7702.11
P/FCF Ratio-1.03
Enterprise Value/Market Cap1.93
Enterprise Value/Revenue12.34K
Enterprise Value/Gross Profit-10.07
Enterprise Value/Ebitda-1.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Targeted Cannabinoid TherapeuticsA focused business model targeting cannabinoid-based medicines gives Zelira a clear therapeutic niche and strategic clarity. Over the medium term this specialization can support differentiated product development, targeted regulatory strategy, and stronger commercial positioning in chronic pain and related markets if execution improves.
Integrated R&D-to-commercial CapabilityHolding R&D, clinical evaluation and regulated commercialisation capabilities reduces reliance on external partners and shortens product commercialization cycles. This vertical integration can preserve margin capture, improve development-to-market execution, and create durable operational advantages versus pure-play developers.
Slight Improvement In Free Cash Flow GrowthNotwithstanding ongoing negatives, a slight improvement in free cash flow growth signals early operational traction or cost discipline. If sustained, improving FCF dynamics strengthen runway, reduce refinancing needs and support continued R&D or commercialization investments over the next several quarters.
Bears Say
Severe Revenue DeclineA ~98% year-over-year revenue drop indicates loss of core sales or product market traction, which is a fundamental weakness. Such a collapse erodes scale economies, undermines margin recovery potential, and limits internal funding for clinical programs or commercial expansion absent a credible revenue-recovery plan.
Negative Equity And Balance-sheet InstabilityNegative shareholders' equity signals capital depletion and raises solvency concerns. This condition constrains borrowing capacity, increases the likelihood of dilutive financing, undermines partner confidence, and reduces strategic flexibility, all of which are durable headwinds to operational scaling and long-term viability.
Persistent Cash BurnOngoing negative operating and free cash flows create continual funding pressure. Persistent cash burn forces management to prioritize financing over product investment, risks dilution from capital raises, and impairs the firm's ability to sustain clinical programs or scale commercial operations without structural cash-flow improvement.
Zelira Therapeutics News
ZLDAF FAQ
What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest stock price was $0.20 and its highest was $0.48 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Zelira Therapeutics’s market cap is $4.18M.
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Sep 02, 2026 which is in 179 days.
How were Zelira Therapeutics’s earnings last quarter?
Currently, no data Available
Is Zelira Therapeutics overvalued?
According to Wall Street analysts Zelira Therapeutics’s price is currently Overvalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 11,897,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in ZLDAF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zelira Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-75.38%
Trailing 12-Months
Company Description
Zelira Therapeutics
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; and the Children's Hospital of Philadelphia. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
Technical Analysis
Invex Therapeutics Ltd.
―
Regeneus Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Neuroscientific Biopharmaceuticals Ltd.
―